Literature DB >> 27935553

Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.

L P Beyer, B Pregler, C Nießen, K Michalik, M Haimerl, C Stroszczynski, E M Jung, P Wiggermann.   

Abstract

PURPOSE: Irreversible electroporation (IRE) is a focal non-thermal ablation technique that can be used to treat prostate cancer (Pca). The objective was to document the evolution of the volume of the prostate gland and the ablation zone after IRE of Pca.
MATERIAL AND METHODS: A retrospective analysis of the image findings of CEUS 1 day, 6 weeks, 3 months and 6 months after IRE of 25 patients was conducted. The prostate gland volumes and the size of the ablation zones were documented. Changes in volume and size over time were calculated.
RESULTS: There was a significant volume reduction of the prostate gland in the first 3 months after ablation. The mean percentage change after 6 weeks was 34.3% with another decrease of 35.0% after 3 months. Volume did not change between month 3 and 6. Size of ablation zone measured in short- and long-axis significantly diminished until 6 months after ablation.
CONCLUSION: CEUS showed a significant involution of the prostate gland during the first 3 months and a significant decrease of the ablation zone during the first 6 months after IRE of prostate cancer.

Entities:  

Keywords:  Contrast-enhanced ultrasound (CEUS); imaging findings; irreversible electroporation (IRE); prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27935553     DOI: 10.3233/CH-168125

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  2 in total

Review 1.  [Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer].

Authors:  P Wiggermann; K Brünn; W Bäumler
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

Review 2.  Contrast-Enhanced Transrectal Ultrasound in Focal Therapy for Prostate Cancer.

Authors:  Akbar N Ashrafi; Nima Nassiri; Inderbir S Gill; Mittul Gulati; Daniel Park; Andre L de Castro Abreu
Journal:  Curr Urol Rep       Date:  2018-08-28       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.